Richard Lipton PT -期刊文章盟盟约书亚·科恩AU -保罗·p·杨盟Ronghua杨Verena Ramirez Campos AU -迈克尔Seminerio盟盟-辛格Rashmi Halker盟杰西卡Ailani TI - Fremanezumab的长期疗效的患者恢复从慢性偏头痛的情景分类(S17.006) DP - 2019年4月09年TA -神经病学PG - S17.006 VI - 92 IP - 15补充4099 - //www.ez-admanager.com/content/92/15_Supplement/S17.006.short 4100 - //www.ez-admanager.com/content/92/15_Supplement/首页S17.006.full所以Neurology2019 4月09年;92 AB -目的:评估的长期疗效fremanezumab成人慢性偏头痛(CM)恢复情景偏头痛(EM)。背景:CM经验更频繁头痛患者和残疾大于EM患者。Fremanezumab,全人源化单克隆抗体(IgG2Δa)选择性目标降钙素相关基因肽(CGRP怎样),在美国被批准用于偏头痛的预防治疗。设计/方法:52周,多中心,随机,双盲,与这些相应平行的组织研究,CM患者接受皮下fremanezumab月(每月225毫克;的起始剂量675毫克)或季度(675毫克每3个月)。这事后分析评价fremanezumab功效的子群病人恢复从CM EM,定义为≥15月头痛天基线和& lt; 15头痛的日子在12月。结果:813 CM患者基线,548年恢复从CM。在这个群,平均每月的头痛天数的变化至少中等严重程度从基线到6月是季度和7.7−−7.6月度计量,从基线到12月是季度和8.5−−8.8月剂量。平均每月的偏头痛天数变化从基线到6月是季度和−−8.9 9.2每月计量;从基线为季度和月12是−10.3−10.4月剂量。任何急性头痛药物使用均值变化从基线到6月是季度和−−7.0 7.2每月计量;从基线为季度和月12是−8.2−8.1月剂量。Conclusions: In patients who reverted from CM to EM, monthly headache days, migraine days, and days of acute headache medication use decreased progressively from baseline to Month 6 and through Month 12 in both dosing groups.Disclosure: Dr. Lipton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with American Academy of Neurology, Alder Biopharmaceuticals, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir Pharmaceuticals, Biohaven, Biovision, Boston Scientific, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, and Vedanta. Dr. Lipton holds stock and/or stock options in Biohaven. Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Teva Pharmaceuticals. Dr. Yeung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Yang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Seminerio has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities as an employee of Teva Pharmaceuticals. Dr. Ramirez Campos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Halker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with WebMD/Medlink, Amgen, and Allergan. Dr. Halker has received personal compensation in an editorial capacity for Current Neurology & Neuroscience Reports. Dr. Ailani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder, Allergan, Amgen, Avanir, Biohavin, Eli Lilly and Company, Electrocore, Promius, Teva, Impel, Satsuma, Aptus, Alpha Sites and Miller Medical Communications. Dr. Ailani has received personal compensation in an editorial capacity for Current Pain and Headache Reports (section editor). Dr. Ailani has received research support from ARMR/American Migraine Foundation and Biohaven.